A randomized multicenter phase II trial to evaluate the effectiveness of selective neoadjuvant treatment according to immunohistochemical subtype for HER2 [human epidermal growth factor receptor-2] negative breast cancer patients.

Trial Profile

A randomized multicenter phase II trial to evaluate the effectiveness of selective neoadjuvant treatment according to immunohistochemical subtype for HER2 [human epidermal growth factor receptor-2] negative breast cancer patients.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs Exemestane (Primary) ; Goserelin (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Results of a genomic analysis from NCT00432172 and NCT00841828 studies presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 21 Nov 2012 Planned end date changed from 1 Dec 2011 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Results published in Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top